ArticleFrontiers in oncology2026
Primary splenic angiosarcoma presenting with multiple bone destruction as the initial manifestation: a case report and narrative review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary splenic angiosarcoma (PSA) is an extremely rare and highly aggressive malignant vascular tumor. Its clinical presentation is often nonspecific, and the diagnosis is frequently delayed. Osseous metastasis as the initial clinical manifestation is particularly uncommon, posing significant diagnostic challenges. A critical yet underappreciated phenomenon is the discordance between histological differentiation and biological behavior in angiosarcoma: well-differentiated tumors can exhibit highly aggressive clinical courses. Furthermore, biopsy of vascular tumors carries a substantial risk of intractable hemorrhage, a complication that is often underestimated. Case introduction: We report the case of a 56-year-old female who presented with a 20-day history of lower back and right hip pain. Imaging revealed multiple osteolytic lesions involving the thoracolumbar vertebrae, pelvis, and sacrum, as well as multiple nodular lesions in the spleen. The initial clinical suspicion favored metastatic disease of unknown primary. Ultrasound-guided needle biopsy of the right iliac lesion yielded abundant hemorrhage but no definitive malignant tissue on initial pathology. Subsequent open biopsy of the L2 spinous process and right iliac bone resulted in life-threatening hemorrhage, necessitating emergency digital subtraction angiography (DSA) and super-selective embolization. Histopathological examination of the surgical specimens revealed a mixed-type vascular neoplasm with partially well-differentiated angiosarcomatous changes, with immunohistochemical positivity for CD31, CD34, ERG, and Fli-1. Remarkably, follow-up pelvic MRI performed only 21 days after the initial scan demonstrated interval enlargement of multiple bone lesions, indicating extraordinarily rapid disease progression despite the high-grade histological appearance. Conclusion: This case highlights several critical clinical considerations for angiosarcoma: (1) When both splenic and skeletal lesions coexist, suspected primary splenic angiosarcoma with bone metastases should be strongly considered; (2) The histological grade may be discordant with biological behavior-high-grade tumors can exhibit highly aggressive courses; (3) Imaging features can mimic benign vascular tumors such as hemangioma; (4) Biopsy of vascular tumors carries a substantial risk of intractable hemorrhage, and pre-procedural angiographic assessment should be considered. This case underscores the importance of integrating clinical, imaging, and pathological findings for accurate diagnosis and management of this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.